
CRDL
Cardiol Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on inflammation and fibrosis in cardiovascular diseases, including acute myocarditis, recurrent pericarditis, and heart failure. The company is developing product candidates using proprietary delivery technologies to target inflamed and fibrotic tissue, with plans to develop multiple routes of administration and formulations for clinical studies and commercialization.